Antimicrobial resistance (AMR) occurs when bacteria, viruses, and fungi change to protect themselves from antimicrobial drugs like antibiotics. The overuse and misuse of antibiotics has accelerated this natural phenomenon and made it a major global health threat. While antibiotic use in humans, agriculture, and livestock all contribute to AMR, appropriate antibiotic stewardship programs that promote judicious use can help reduce the problem. New diagnostic tools and treatments are also needed to address the growing issue of drug-resistant tuberculosis, especially among children.
For decades microbes, in particular bacteria, have become increasingly resistant to various antimicrobials.
The World Health Assembly’s endorsement of the Global Action Plan on Antimicrobial Resistance (AMR) in May 2015, and the Political Declaration of the High-Level Meeting of the General Assembly on AMR in September 2017, both recognize AMR as a global threat to public health.
These policy initiatives acknowledge overuse and misuse of antimicrobials as a main driver for development of resistance, as well as a need to optimize the use of antimicrobials.
The Global Action Plan on AMR sets out five strategic objectives as a blueprint for countries in developing national action plans (NAPs) on AMR:
Objective 1: Improve awareness and understanding of AMR through effective communication, education and training.
Objective 2: Strengthen the knowledge and evidence base through surveillance and research.
Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.
Objective 4: Optimize the use of antimicrobial medicines in human and animal health.
Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions.
Antimicrobial stewardship programmes optimize the use of antimicrobials, improve patient outcomes, reduce AMR and health-care-associated infections, and save health-care costs amongst others.
Today, AMS is one of three “pillars” of an integrated approach to health systems strengthening. The other two are infection prevention and control (IPC) and medicine and patient safety.
Linking all three pillars to other key components of infection management and health systems strengthening, such as AMR surveillance and adequate supply of quality assured medicines, promotes equitable and quality health care towards the goal of achieving universal health coverage
CDC has defined “Antimicrobial stewardship” as-
The right antibiotic
for the right patient,
at the right time,
with the right dose, and
the right route, causing
the least harm to the patient and future patients
Why AMSP is needed?
Antimicrobial Resistance (AMR)
Misuse and Over-use of Antimicrobials
Widespread Use of Antimicrobials in Other Sectors
Poor Antimicrobial Research
IMPLEMENTATION OF ANTIMICROBIAL STEWARDSHIP PROGRAM
Administrative Support (Leadership)
Formulating AMS Team
Infrastructure Support
Framing Antimicrobial Policy
Implementing AMS strategies
Education and Training
Should be publicly committed to the program.
Provide necessary funding and infrastructure support.
Multidisciplinary committee - responsible for framing, implementing and monitoring the compliance to antimicrobial policy of the hospital.
Led by the antimicrobial steward - infectious disease physician or infection control officer or clinical microbiologist.
Other members of AMS team - stewardship nurses
For decades microbes, in particular bacteria, have become increasingly resistant to various antimicrobials.
The World Health Assembly’s endorsement of the Global Action Plan on Antimicrobial Resistance (AMR) in May 2015, and the Political Declaration of the High-Level Meeting of the General Assembly on AMR in September 2017, both recognize AMR as a global threat to public health.
These policy initiatives acknowledge overuse and misuse of antimicrobials as a main driver for development of resistance, as well as a need to optimize the use of antimicrobials.
The Global Action Plan on AMR sets out five strategic objectives as a blueprint for countries in developing national action plans (NAPs) on AMR:
Objective 1: Improve awareness and understanding of AMR through effective communication, education and training.
Objective 2: Strengthen the knowledge and evidence base through surveillance and research.
Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.
Objective 4: Optimize the use of antimicrobial medicines in human and animal health.
Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions.
Antimicrobial stewardship programmes optimize the use of antimicrobials, improve patient outcomes, reduce AMR and health-care-associated infections, and save health-care costs amongst others.
Today, AMS is one of three “pillars” of an integrated approach to health systems strengthening. The other two are infection prevention and control (IPC) and medicine and patient safety.
Linking all three pillars to other key components of infection management and health systems strengthening, such as AMR surveillance and adequate supply of quality assured medicines, promotes equitable and quality health care towards the goal of achieving universal health coverage
CDC has defined “Antimicrobial stewardship” as-
The right antibiotic
for the right patient,
at the right time,
with the right dose, and
the right route, causing
the least harm to the patient and future patients
Why AMSP is needed?
Antimicrobial Resistance (AMR)
Misuse and Over-use of Antimicrobials
Widespread Use of Antimicrobials in Other Sectors
Poor Antimicrobial Research
IMPLEMENTATION OF ANTIMICROBIAL STEWARDSHIP PROGRAM
Administrative Support (Leadership)
Formulating AMS Team
Infrastructure Support
Framing Antimicrobial Policy
Implementing AMS strategies
Education and Training
Should be publicly committed to the program.
Provide necessary funding and infrastructure support.
Multidisciplinary committee - responsible for framing, implementing and monitoring the compliance to antimicrobial policy of the hospital.
Led by the antimicrobial steward - infectious disease physician or infection control officer or clinical microbiologist.
Other members of AMS team - stewardship nurses
In India, bacteria that cause common infections, such as urinary tract and bloodstream infections, are becoming resistant to nearly all antibiotics. This resistance is due to a combination of factors: uncontrolled access to antibiotics, gaps in infection prevention and control (IPC) practices, and high rates of communicable diseases. Antibiotic resistance, or AR, is a serious problem throughout the country, and threatens to reduce the usefulness of antibiotics both in India and around the world.
Because of this emerging threat, India is committed to slowing the spread of AR. Two institutions within India’s Ministry of Health – the Indian Council of Medical Research and National Centre for Disease Control – each developed national networks of public and private hospitals to measure AR trends, prevent healthcare-associated infections (HAIs), and enhance appropriate use of antibiotics. The All India Institute of Medical Sciences is coordinating HAI measurement and prevention efforts in both networks. In addition, efforts in the state of Tamil Nadu focus on building district-level IPC capacity to prevent HAIs, focusing on maternal and neonatal patients.
The Indian Governamnet is is working closely with partners at the national and state level to:
Detect AR pathogens, including novel strains, by developing lab networks and lab expertise.
Use standardized surveillance to monitor and track AR infections in healthcare to learn how often these infections occur and to help develop strategies to prevent them.
Implement focused IPC activities and training.
Optimize use and reduce misuse of critical antibiotics through antibiotic stewardship programs.
overuse and misuse of antibiotic put all of us at danger, and help to develop drug-resistant bacteria, so-called superbugs. which ultimately increase the cost of health care. so the third world countries are facing a burden of an extra charge of expenditure and unusual death
CDC Key Prevention Strategies for Antimicrobial Resistance Prevent Infection Step 1: Vaccinate Fact:
Influenza and pneumococcal vaccination of at-risk hospital patients and influenza vaccination of healthcare personnel will prevent infections.
Step 2: Get the catheters out Fact:
Catheters and other invasive devices are the # 1 exogenous cause of hospital-onset infections.
Diagnose & Treat Infection Effectively Step 3: Target the pathogen
Fact:
Appropriate antimicrobial therapy saves lives.
Step 4: Access the experts Fact:
Infectious diseases expert input improves the outcome of serious infections.
•
Use Antimicrobials Wisely
Step 5: Practice antimicrobial control Fact:
Programs to improve antimicrobial use are effective. (Antimicrobial Stewardship)
•
Step 6: Use local data
Fact:
The prevalence of resistance can vary by locality, patient population, hospital unit, and length of stay.
•
•
Step 7: Treat infection, not contamination Fact:
A major cause of antimicrobial overuse is “treatment” of contaminated cultures.
Step 8: Treat infection, not colonization Fact:
Step 9: Know when to say “no” to vancomycin Fact:
Vancomycin overuse promotes emergence, selection,and spread of resistant pathogens.
•
Step 10: Stop antimicrobial treatment Fact:
Failure to stop unnecessary antimicrobial treatment contributes to overuse and resistance.
Prevent Transmission
Step 11: Isolate the pathogen Fact:
Patient-to-patient spread of pathogens can be prevented.
•
Step 12: Break the chain of infection Fact:
Healthcare personnel can spread antimicrobial-resistant pathogens from patient to patient
Antimicrobial stewardship; is an activity that includes appropriate selection, dosing, route, and duration of antimicrobial therapy…..
Why is Antimicrobial Stewardship Important?
200-300 million antibiotics are prescribed annually….45% for outpatient use
25-40% of hospitalized patients receive antibiotics
10-70% are unnecessary or suboptimal
5% of hospitalized patients who receive antibiotics experience an Adverse reaction.
Health insurance companies will no longer reimburse for hospital acquired conditions deemed preventable.
Why is an antibiotic policy necessary?
To improve patient care by considered use of antibiotics for prophylaxis and therapy.
To rationalize the use of antibiotics.
To prevent or retard the emergence of resistant strains.
To improve education of junior doctors by providing guidelines for appropriate therapy
What are the clinical uses of antibiotics :
1. Therapeutic use:-
It is administration of an antimicrobial agent where substantial microbial infection has occurred.
2. Prophylactic Use:-
It is the use of antimicrobial agent before any infection has occurred to prevent a subsequent infection.
The Antimicrobial Stewardship Program (ASP) should be administered by multidisciplinary team (AST) composed of:
an infectious diseases (ID)physician
a clinical pharmacist with ID training,
a clinical microbiologist,
an IC professional,
Antibioti
World Veterinary Day 2017 Presentation made at the College of Veterinary and Animal Science, Navania, Vallabhnagar, Udaipur by DR. BALWANT MESHRAM on the topic 'WVD: Past and the Present'
In India, bacteria that cause common infections, such as urinary tract and bloodstream infections, are becoming resistant to nearly all antibiotics. This resistance is due to a combination of factors: uncontrolled access to antibiotics, gaps in infection prevention and control (IPC) practices, and high rates of communicable diseases. Antibiotic resistance, or AR, is a serious problem throughout the country, and threatens to reduce the usefulness of antibiotics both in India and around the world.
Because of this emerging threat, India is committed to slowing the spread of AR. Two institutions within India’s Ministry of Health – the Indian Council of Medical Research and National Centre for Disease Control – each developed national networks of public and private hospitals to measure AR trends, prevent healthcare-associated infections (HAIs), and enhance appropriate use of antibiotics. The All India Institute of Medical Sciences is coordinating HAI measurement and prevention efforts in both networks. In addition, efforts in the state of Tamil Nadu focus on building district-level IPC capacity to prevent HAIs, focusing on maternal and neonatal patients.
The Indian Governamnet is is working closely with partners at the national and state level to:
Detect AR pathogens, including novel strains, by developing lab networks and lab expertise.
Use standardized surveillance to monitor and track AR infections in healthcare to learn how often these infections occur and to help develop strategies to prevent them.
Implement focused IPC activities and training.
Optimize use and reduce misuse of critical antibiotics through antibiotic stewardship programs.
overuse and misuse of antibiotic put all of us at danger, and help to develop drug-resistant bacteria, so-called superbugs. which ultimately increase the cost of health care. so the third world countries are facing a burden of an extra charge of expenditure and unusual death
CDC Key Prevention Strategies for Antimicrobial Resistance Prevent Infection Step 1: Vaccinate Fact:
Influenza and pneumococcal vaccination of at-risk hospital patients and influenza vaccination of healthcare personnel will prevent infections.
Step 2: Get the catheters out Fact:
Catheters and other invasive devices are the # 1 exogenous cause of hospital-onset infections.
Diagnose & Treat Infection Effectively Step 3: Target the pathogen
Fact:
Appropriate antimicrobial therapy saves lives.
Step 4: Access the experts Fact:
Infectious diseases expert input improves the outcome of serious infections.
•
Use Antimicrobials Wisely
Step 5: Practice antimicrobial control Fact:
Programs to improve antimicrobial use are effective. (Antimicrobial Stewardship)
•
Step 6: Use local data
Fact:
The prevalence of resistance can vary by locality, patient population, hospital unit, and length of stay.
•
•
Step 7: Treat infection, not contamination Fact:
A major cause of antimicrobial overuse is “treatment” of contaminated cultures.
Step 8: Treat infection, not colonization Fact:
Step 9: Know when to say “no” to vancomycin Fact:
Vancomycin overuse promotes emergence, selection,and spread of resistant pathogens.
•
Step 10: Stop antimicrobial treatment Fact:
Failure to stop unnecessary antimicrobial treatment contributes to overuse and resistance.
Prevent Transmission
Step 11: Isolate the pathogen Fact:
Patient-to-patient spread of pathogens can be prevented.
•
Step 12: Break the chain of infection Fact:
Healthcare personnel can spread antimicrobial-resistant pathogens from patient to patient
Antimicrobial stewardship; is an activity that includes appropriate selection, dosing, route, and duration of antimicrobial therapy…..
Why is Antimicrobial Stewardship Important?
200-300 million antibiotics are prescribed annually….45% for outpatient use
25-40% of hospitalized patients receive antibiotics
10-70% are unnecessary or suboptimal
5% of hospitalized patients who receive antibiotics experience an Adverse reaction.
Health insurance companies will no longer reimburse for hospital acquired conditions deemed preventable.
Why is an antibiotic policy necessary?
To improve patient care by considered use of antibiotics for prophylaxis and therapy.
To rationalize the use of antibiotics.
To prevent or retard the emergence of resistant strains.
To improve education of junior doctors by providing guidelines for appropriate therapy
What are the clinical uses of antibiotics :
1. Therapeutic use:-
It is administration of an antimicrobial agent where substantial microbial infection has occurred.
2. Prophylactic Use:-
It is the use of antimicrobial agent before any infection has occurred to prevent a subsequent infection.
The Antimicrobial Stewardship Program (ASP) should be administered by multidisciplinary team (AST) composed of:
an infectious diseases (ID)physician
a clinical pharmacist with ID training,
a clinical microbiologist,
an IC professional,
Antibioti
World Veterinary Day 2017 Presentation made at the College of Veterinary and Animal Science, Navania, Vallabhnagar, Udaipur by DR. BALWANT MESHRAM on the topic 'WVD: Past and the Present'
Similar to ANTIBOITICS TO RESISTANCE. MENACE TO CONTROL.pptx (20)
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
2. What is antimicrobial resistance (AMR)?
Antimicrobial resistance (AMR) occurs when bacteria, parasites, viruses or fungi change to protect
themselves from the effects of antimicrobial drugs designed to destroy them.
This means previously effective antimicrobial drugs (e.g. antibiotics) used to treat or prevent
infections may no longer work.
The World Health Organization (WHO) has identified AMR as ‘one of the biggest threats to global
health’.
The Australia’s National Antimicrobial Resistance Strategy - 2020 and Beyond was released and is
Australia’s national AMR strategy.
https://www.nps.org.au/medical-info/consumer-info/antibiotic-resistance-the-facts
3. Why are antibiotics and antimicrobial resistance
important?
Antibiotics treat infections caused by bacteria
• Currently, antibiotics reduce post-operative infection rates to below 2%
• Without effective antibiotics, this could increase to around 40% to 50%. Up to 30% of
these patients could die from resistant bacterial infections
• The risk of mortality without access to effective antibiotics may make some treatments
and surgical procedures too risky to continue
Modern medicine, especially surgery and cancer treatments,
depends on effective antibiotics to minimise the risk of infection
Antimicrobial resistance results in substantial financial cost for
patients and healthcare systems.
https://www.vox.com/2014/12/12/7382299/new-report-drug-resistant-infections-will-kill-more-people-than
5. Antibiotics are a unique medicine
In general, the impact of medications are limited to the patient taking them
Use of antibiotics has an impact not just for the patient using them but the global community
as well
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011
Apr;86(4):304-14. doi: 10.4065/mcp.2010.0575. Epub 2011 Mar 9. PMID: 21389250; PMCID:
PMC3068890.
6. How has antimicrobial resistance developed?
Antimicrobial resistance is a natural phenomenon
Overuse, misuse and inappropriate use of antibiotics may accelerate this
The delivery of more complex health care which may require longer use of antibiotics
Prolonged hospitalisation
The potential impact of surgical procedures undertaken overseas
• During hospitalisation if infection prevention is poor
• Potential for cross-border transmission through increased travel.
Resistant pathogens can now spread easily
Priyadharsini, Raman Palanisamy. "Antibiotic resistance: what is there in past, present and future?." Journal of Young Pharmacists 11.4 (2019): 333.
7. Where do we use antibiotics?
• Community
• Hospital
Humans
• Pets
• Livestock
Animals
• Crops
• Aquaculture
Agriculture
Priyadharsini, Raman Palanisamy. "Antibiotic resistance: what is there in past, present and future?." Journal of Young Pharmacists 11.4 (2019): 333.
12. 1.27 millions Deaths Direct Result of
Antibiotic Resistance Infections
Antimicrobial Resistance Collaborators. Lancet 2022; 399: 629–55
13. Volume and Share of Antibiotic Classes
Consumed in the Private Sector in India
Shaffi Fazaludeen Koya et al. The Lancet Regional Health - Southeast Asia. 2022;4: 100025
DDD – Defined Daily Dose
15. Characteristics of the Top Four Antibiotic Class
Shaffi Fazaludeen Koya et al. The Lancet Regional Health - Southeast Asia. 2022;4: 100025
16. Factors Contributing in Antibiotic Resistance in India
• The per-capita private-sector consumption rate of antibiotics in India is relatively
low compared to many countries.
• Still, India consumes a large volume of broad-spectrum antibiotics that should
ideally be used sparingly.
• In addition to this, there is a significant share of FDCs from formulations outside
NLEM and a large volume of antibiotics not approved by the central drug
regulators that calls for significant policy and regulatory reform.
Shaffi Fazaludeen Koya et al. The Lancet Regional Health - Southeast Asia. 2022;4: 100025
17. Antimicrobial
Stewardship Programmes
A WHO Practical Toolkit
Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. A practical
toolkit. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
18. Classification of Use of Antibiotics
• The WHO EML AWaRe classification of commonly used antibiotics into three
groups –
ACCESS
WATCH
RESERVE
Provides a tool to support antibiotic monitoring and AMS activities, with
recommendations on when to use
26. Percentage of Cases of Tuberculosis in
Pacific Region of the Earth
Chowdhury K et al. Cureus 15(2): e35154. doi:10.7759/cureus.35154
27. Multidrug-resistant TB and Extensively Drug-resistant TB
Chowdhury K et al. Cureus 15(2): e35154. doi:10.7759/cureus.35154
28. Various Challenges for Diagnosing and Treating
Drug-Resistant Tuberculosis Among the Pediatric Population
Chowdhury K et al. Cureus 15(2): e35154. doi:10.7759/cureus.35154
29. Factors Causing Raised Caseloads of DR-TB
Under-
reporting
Lack of proper
diagnostic
tools
Less
accessibility to
the health care
system
Unavailability
of suitable
pediatric drugs
against DR-TB
COVID-19
pandemic
Chowdhury K et al. Cureus 15(2): e35154. doi:10.7759/cureus.35154
Antimicrobial resistance is one of the most significant challenges for the provision of safe, high-quality health services across the world. The term ‘antimicrobial resistance’ refers to the failure of an antimicrobial (which includes antibiotics) to inhibit or destroy bacteria, parasites, viruses or fungi for which it has been designed using standard dosing regimens
Antimicrobial resistance has a direct effect on patient care and creates a set of critical ongoing challenges to health service delivery. It can increase a patient’s length of hospital stay and severity of patient illness. Severe infections caused by bacteria that do not respond to available ‘last-line’ antimicrobials (including antibiotics) can result in septicaemia and death.
Antimicrobial resistance also increases the complexity of treatment, and places a significant burden on patients, health service organisations and the health system.
Amina J. Mohammed (Deputy Secretary-General of the UN) was quoted as saying that “Antimicrobial resistance is one of the most pressing issues globally, not only for human health but it is a multi-sectoral problem involving animal health, agriculture, the environment, trade and many other sectors”.
Dr Tedros Adhanom Ghebreyesus, Director-General of WHO was quoted as saying “A lack of effective antibiotics is as serious a security threat as a sudden and deadly disease outbreak. Strong, sustained action across all sectors is vital if we are to turn back the tide of antimicrobial resistance and keep the world safe."
Prof Dame Sally Davies, England’s chief medical officer was quoted as saying “We will be given the choice of, well you can have an expensive treatment that’s likely to cure you, but you’ll get an infection that is likely to be resistant and you’ll probably die of it,” she told MPs. “Meanwhile all transplants will be out of the window because they are all prone to infections. There will be a lot of suffering and modern medicine will be lost.”
NPS MedicineWise maintains a list of important antibiotic resistance myths:
https://www.nps.org.au/medical-info/consumer-info/antibiotic-resistance-the-facts
Consumers are aware that antibiotics treat infections. However, consumers may not be aware that antibiotics are essential in preventing infection after surgical procedures and for patients receiving chemotherapy.
Antimicrobial resistance has significant and direct implications on patient care. Antibiotics play an essential role in preventing infection after surgery. For example, people currently undergoing surgery procedures (such as hip and knee replacements) receive standard prophylactic antibiotics and currently experience infection rates of around 0.5-2.0%. If access to effective antibiotics were reduced through antimicrobial resistance, post-operative infection rates could rise to around 40-50%, and up to 30% of these patients could die from these infections.
Antimicrobial resistance also impacts on a range of treatment options, such as chemotherapy for cancer patients, which may no longer be a viable or safe option due to the increased risk of complications and infections resulting post treatment. This reduction in safe and viable treatments, and services able to be offered by health facilities, would have a negative effect on the effectiveness of the healthcare system in the long term.
In 2014 the UK Government commissioned a review on antimicrobial resistance which investigated the global economic cost of infections caused by resistant bacteria. The work by KPMG and RAND Europe indicated that if the current trend of increasing antimicrobial resistance continues, by 2050 about 10 million people may die every year as a direct result of resistant bacterial infections for which there is no effective antimicrobial (which includes antibiotics). Gross domestic product would also decrease as a result of antimicrobial resistance, which the review indicated would translate to a reduction in global economic output worth between US$60 - US$100 trillion.
https://www.vox.com/2014/12/12/7382299/new-report-drug-resistant-infections-will-kill-more-people-than
Antimicrobial resistance occurs when bacteria develop resistance to an antimicrobial that was previously an effective treatment. Bacteria develop natural defences against antibiotics. When this occurs, potentially due to prolonged exposure to or overuse of a particular antibiotic, the antibiotic’s effectiveness to treat the infection decreases, and may reach a point where the antibiotic has no benefit.
The overuse of antibiotics in health (human and animal) and agriculture has increased the amount of exposure bacteria have to them, giving bacteria more opportunity to develop resistance. The process of natural selection (‘survival of the fittest’ – favouring bacteria that develop the strongest natural defences) fuels the increasing prevalence of antimicrobial resistance.
New challenges in infection control resulting from more complex health care (for example, outpatient chemotherapy) and increasing domestic and international travel have increased the spread of resistant bacteria both between individuals and between countries.
When patients have longer hospital stays, this may increase the chance of patients acquiring resistant organisms from other patients.
Addressing the rising threat of antimicrobial resistance (AMR) requires a holistic and multisectoral approach – referred to as One Health – because antimicrobials used to treat various infectious diseases in animals may be the same or similar to those used for humans. Resistant bacteria arising in humans, animals or the environment may spread from one to the other, and from one country to another. AMR does not recognise geographic or human–animal borders. - https://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistance/policy/one-health
Antibiotics resistance can spread by many vectors.
In an interview shortly after winning the Nobel Prize in 1945 for discovering penicillin, Alexander Fleming said: “The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.”
You may wish to play this TED talk on antibiotic resistance - https://www.youtube.com/watch?v=o3oDpCb7VqI&app=desktop
This graph shows Carbapenemase producing Enterobacteriaceae (CPE) becoming more prevalent over a two year period in Europe.